ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2388

Increased Risk of Severe Infections in Early Giant Cell Arteritis: A Population- based Study

Nazanin Naderi1, Aladdin Mohammad2, Karin Wadström3, Ulf Bergström3 and Carl Turesson3, 1Lund University, Kristiandstad, Sweden, 2Lund University, Lund, Sweden, 3Lund University, Malmö, Sweden

Meeting: ACR Convergence 2023

Keywords: giant cell arteritis, Infection

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2387–2424) Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Giant cell arteritis (GCA) is the most common type of vasculitis in adults aged 50 years or older. Although the substantial morbidity from infections in patients with GCA, partly due to immunosuppressive treatment, is well recognized, few studies have evaluated the incidence of severe infections compared to the general population. Even fewer have investigated the incidence of severe infection by time from GCA diagnosis compared to a reference population.

The objective of this study was to compare the risk of severe infection in different time intervals after GCA diagnosis to the general population.

Methods: Patients with biopsy-proven GCA, diagnosed between 2002 and 2010 were retrieved from a regional pathology register. They were compared with four reference subjects per case from the corresponding area, matched for age, sex and area of residence. Data on infections requiring hospitalization were obtained from linkage of the cases and the references to the regional healthcare register, through 2011. Using ICD-10 codes, twenty categories of infections were identified. Patients and reference subjects were censored at death or migration from the area. Incidence rates of severe infections in patients with GCA and reference subjects, stratified by follow-up time (0-6 months, 6-12 months, 1-2 years, 2-3 years, > 3 years), were estimated by dividing the number of severe infections in each time interval with the corresponding follow-up time (in years). The follow-up time started at date of diagnosis for patients (index-date for reference subjects) and ended at death or December 31, 2011. Rate Ratios (RRs) regarding severe infections, stratified by category of follow-up time, were calculated for patients with GCA vs. reference subjects. The 95% confidence intervals (CI) for incidence rates and RRs were estimated using the Poisson distribution ratio.

Results: Five hundred and sixteen patients with GCA were identified and compared to 3335 matched reference subjects. A total of 222 severe infections occurred in 118 patients with GCA. The cumulative incidence rate of severe infections was 8.5 % during the first year and 22.9 % over the entire follow-up.

The incidence rate in patients with GCA was highest during the first six months, 14.8/100 person-years (Table 1).

During this period, the rate was significantly increased compared to reference subjects (RR 3.27; 95% CI 2.06; 5.11) (Figure 1).

The rate of severe infections was numerically higher than that for the general population during the entire follow-up, but the difference reached statistical significance only during the first six months and after > 2 years of follow-up (Table 1, Figure 1).

Conclusion: The risk for severe infection is increased in patients with GCA compared to the general population, in particular during the first 6 months after diagnosis.

Supporting image 1

Table 1

Supporting image 2

Figure 1


Disclosures: N. Naderi: None; A. Mohammad: None; K. Wadström: None; U. Bergström: None; C. Turesson: AbbVie/Abbott, 6, Bristol-Myers Squibb(BMS), 5, Pfizer, 6.

To cite this abstract in AMA style:

Naderi N, Mohammad A, Wadström K, Bergström U, Turesson C. Increased Risk of Severe Infections in Early Giant Cell Arteritis: A Population- based Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/increased-risk-of-severe-infections-in-early-giant-cell-arteritis-a-population-based-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-risk-of-severe-infections-in-early-giant-cell-arteritis-a-population-based-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology